Evidence map›Paper›PMID 35629967›Full record

ArticleMetabolites2022

Intestinal Absorption Study of a Granular Form of Ferric Pyrophosphate.

Marta Micheletto, Elisa Gaio, Erik Tedesco, Giovanni Di Maira, Etienne Mantovan, Michela Zanella, Paolo Pastore, Marco Roverso, Gabriella Favaro, Federico Benetti

Abstract read
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marta MichelettoECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, 35127 Padova, Italy.ORCID 0000-0003-4911-7755
Elisa GaioECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, 35127 Padova, Italy.
Erik TedescoECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, 35127 Padova, Italy.ORCID 0000-0003-3514-3004
Giovanni Di MairaECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, 35127 Padova, Italy.
Etienne MantovanECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, 35127 Padova, Italy.
Michela ZanellaECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, 35127 Padova, Italy.
Paolo PastoreDepartment of Chemical Sciences, University of Padova, 35131 Padova, Italy.ORCID 0000-0003-1448-0175
Marco RoversoDepartment of Chemical Sciences, University of Padova, 35131 Padova, Italy.ORCID 0000-0003-1264-8878
Gabriella FavaroDepartment of Chemical Sciences, University of Padova, 35131 Padova, Italy.
Federico BenettiECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, 35127 Padova, Italy.ORCID 0000-0001-6491-4715

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency is one of the most prevalent nutritional disorders worldwide. The standard treatment involves iron supplementation, but this task is challenging because of poor solubility and organoleptic issues. Moreover, the need to increase iron bioavailability represents a challenge for treating iron-related disorders. In this study, gastroresistance and iron intestinal absorption of an innovative granular formulation composed of ferric pyrophosphate, modified starch and phospholipids branded as Ferro Fosfosoma

Indexed as

delivery systemsdietary supplementsferritinintestinal absorptioniron

Identifiers

PMID35629967
PMCPMC9145852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.